alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 642 studies published 2011 (page 6 of 26) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA 2011-01-01

Lower plasma β-amyloid 42 and 42/40 levels have been associated with incident dementia, but results are conflicting and few have investigated cognitive decline among elders without dementia. 4 key findings →

Participants: 550 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Annals of neurology 2011-03-11

There is a clear need to develop biomarkers for Parkinson disease (PD) diagnosis, differential diagnosis of Parkinsonian disorders, and monitoring disease progression. 4 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Archives of general psychiatry 2011-09-01

Biomarkers have become increasingly important in understanding neurodegenerative processes associated with Alzheimer disease. 4 key findings →

Design: longitudinal study Participants: 116 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The effect of comorbidity burden on health care utilization for patients with cancer using hospice

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of palliative medicine 2011-05-06

These findings underscore the complexity of the hospice patient population and highlight a potential need to risk adjust the per diem hospice reimbursement rates to account for increased resource requirements for hospices serving patients with higher comorbidity burden. 4 key findings →

Design: cross-sectional Participants: 27,166 Evidence: low

Full summary, score breakdown and related studies → Original source

Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study

✓ Peer-reviewed alzhub usefulness score 60 out of 100. The British journal of dermatology 2011-07-28

Patients with BP are more likely to have various neurological diseases, schizophrenia and psoriasis prior to the diagnosis of BP, supporting associations found in other studies. 3 key findings →

Design: case-control study Participants: 3,485 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Age-related changes in the default mode network are more advanced in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2011-10-05

The results of this study indicate that the DMN abnormalities observed in patients with AD represent an accelerated aging pattern of connectivity compared with matched controls. 3 key findings →

Participants: 28 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2011-07-01

Individuals with AD and VaD have higher Hct levels than controls; however, a causal relationship between high-Hct level and risk of developing dementia is not supported. 5 key findings →

Design: meta-analysis Participants: 6,122 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Clinical nutrition (Edinburgh, Scotland) 2011-01-08

Homocysteine lowering in dementia patients did not significantly reduce global cognitive decline. 3 key findings →

Participants: 140 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A randomized controlled trial of an activity specific exercise program for individuals with Alzheimer disease in long-term care settings

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of geriatric physical therapy (2001) 2011-04-01

Subjects receiving the activity specific exercise program improved in ability to perform transfers, whereas subjects in the other 2 groups declined. 2 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. The Journal of clinical psychiatry 2011-09-06

In AD patients with symptoms of psychosis, agitation, or aggressive behavior, medications can have a small but significant impact on caregiver burden. 4 key findings →

Design: clinical trial Participants: 361 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Glucose tolerance status and risk of dementia in the community: the Hisayama study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2011-09-01

The age- and sex-adjusted incidence of all-cause dementia, Alzheimer disease (AD), and vascular dementia (VaD) were significantly higher in subjects with diabetes than in those with normal glucose tolerance. 3 key findings →

Participants: 1,017 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2011-12-14

Baseline CSF was collected from 512 patients with Alzheimer disease (AD) and 272 patients with other types of dementia (OD), 135 patients with a psychiatric disorder (PSY), and 275 patients with subjective memory complaints (SMC). 4 key findings →

Participants: 512 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The dynamics of cortical and hippocampal atrophy in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Archives of neurology 2011-08-01

Alzheimer disease-specific cortical thinning and hippocampal volume loss are consistent with a sigmoidal pattern, with an acceleration phase during the early stages of the disease. 2 key findings →

Design: case-control study Participants: 317 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011-05-01

This relationship was evident even after accounting for degree of memory deficit across the continuum of cognitive impairment and dementia. 2 key findings →

Participants: 793 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed